Podcasts

Articles

Webinars

Peer-Reviewed

Videos

ASCO: American Society of Clinical Oncology

Christopher Arendt, PhD, head, Oncology Therapeutic Area Unit, Takeda, speaks on the success of tyrosine kinase inhibitors (TKIs) in the treatment of blood cancers and efficacy implications of these therapies for solid tumor cancers. 

Dr Christopher Arendt on Indication of TKIs in Solid Tumor and Blood Cancers

Christopher Arendt, PhD, head, Oncology Therapeutic Area Unit, Takeda, speaks on the efficacy data of mobocertinib in patients with EGFR exon 20 mutations within metastatic non–small cell lung cancer (NSCLC) and its potential significance for these patient populations. 

Dr Christopher Arendt on Positive Mobocertinib Results Seen in Metastatic NSCLC

Christopher Arendt, PhD, head of the Oncology Therapeutic Area Unit at Takeda, discusses pathogenesis and characteristics of EGFR exon 20 mutations in metastatic non–small cell lung cancer (NSCLC).

Dr Christopher Arendt Explains Mutually Exclusive Nature of EGFR Exon 20 Mutations in Metastatic NSCLC

Camille Hertzka, vice president and head of Oncology, US Medical, AstraZeneca, speaks about the real-world data collection of durvalumab to assess applicability in patients not involved in the PACIFIC trial, and the importance of diversity and inclusion in clinical trials moving forward.

Camille Hertzka on Real-World Implications of Durvalumab, Increasing Diversity in Clinical Trials 

Larry D. Anderson Jr, MD, PhD, associate professor, Harold C. Simmons Comprehensive Cancer Center, discusses updated findings of the phase II KarMMa trial assessing ide-cel chimeric antigen receptor (CAR) T-cell therapy for treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior lines of therapy.

Dr Larry D. Anderson Jr on Updated Phase 2 KarMMa Findings, Implications of COVID-19 for CAR T-Cell Therapy

Camille Hertzka, vice president and head of oncology, US Medical, AstraZeneca, speaks on how the OlympiA findings may warrant greater need of genetic testing for BRCA mutation and the efficacy of olaparib by patient subgroup.

Camille Hertzka on Implications of OlympiA Findings for Screening, Efficacy of Olaparib in BRCA+ Breast Cancer

Rajat Bannerji, MD, PhD, Chief, Section of Hematologic Malignancies at Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, speaks on the efficacy and safety findings of the CAPTIVATE study examining the fixed-duration regimen of ibutinib and venetoclax combination therapy in CLL.

Dr Rajat Bannerji Discusses CAPTIVATE Findings of Ibrutinib, Venetoclax Fixed-Duration Treatment in CLL

Camille Hertzka, vice president and head of Oncology, US Medical, AstraZeneca, discussed updated findings of the PACIFIC trial that indicated a third of patients with unresectable non-small cell lung cancer are stable at 5 years.

Camille Hertzka Addresses 5-Year PACIFIC Trial Findings, Future Ambitions for Durvalumab

The study's lead author said researchers have searched for a generation for an effective therapy to give to high-risk patients with renal cell carcinoma after initial surgery for the tumor.

“Practice-Changing” Results Seen for Pembrolizumab in Adjuvant Setting in Renal Cell Carcinoma

Antoine Italiano, MD, PhD, head of Early Phase Trials and Sarcoma Units at Institut Bergonié, Bordeaux, France, addresses findings of an extended follow-up of larotrectinib in patients with TRK fusion cancer that indicated prolonged progression-free survival in those undergoing the NTRK inhibitor.